Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study
Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.
Inclusion Criteria: People who scheduled themselves for a SGB in our clinics in Colorado.
-
Exclusion Criteria:
Stellate Ganglion Block Contraindications
-